

Anika Therapeutics to Present at Canaccord Genuity Musculoskeletal Conference March 24

BEDFORD, Mass.--(BUSINESS WIRE)-- <u>Anika Therapeutics, Inc.</u> (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the 10th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 24, 2015 at 12:30 p.m. ET/ 9:30 a.m. PT. The conference is being held at the MGM Grand Hotel in Las Vegas, Nevada.

A live audio webcast of the presentation may be accessed via the "<u>Investor Relations</u>" section of Anika's website at <u>www.anikatherapeutics.com</u>. An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., <u>Anika Therapeutics, Inc.</u> develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on <u>hyaluronic acid</u> (<u>HA</u>), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by <u>Orthovisc</u> and <u>Monovisc</u>, treatments for osteoarthritis of the knee, to surgical aids in the <u>anti-adhesion</u> and <u>ophthalmic</u> fields. The Company also offers <u>aesthetic dermal fillers</u> for the correction of facial wrinkles. Anika's Italian subsidiary, Anika Therapeutics S.r.l., provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in areas such as advanced wound treatment and ear, nose and throat care. Its regenerative technology advances Anika's vision to offer therapeutic products and medical solutions that go beyond pain relief to protect and restore damaged tissue.

Anika Therapeutics, Inc. Charles H. Sherwood, Ph.D., 781-457-9000 President and CEO or Sylvia Cheung, CFO, 781-457-9000

Source: Anika Therapeutics, Inc.

News Provided by Acquire Media

https://ir.anika.com/Anika-Therapeutics-to-Present-at-Canaccord-Genuity-Musculoskeletal-Conference-March-24